The problem
High blood pressure or hypertension (HT)
is a silent killer
In the US alone, almost 1M people die
from direct consequences of HT every year
The annual healthcare cost of HT is $370B
and increases every year
Sources: CDC, Circulation 2012, Circulation Research 2019
116M
are hypertensive in the US
93M
do not have it under control
45M
Non-adherent
20M
Drug-resistant
State of the art
8 classes of anti-HT medications
developed over the past 60 years
Increasing drug-resistance prevalence
Burden of daily medication intake
Inefficiency of trial-and-error regime adjustments
Recent FDA-approval of renal denervation therapies (RDN) as a non-pharma alternative
Irreversible effects on the nervous system
Limited efficacy (up to 6mmHg reduction)
Drug-resistant population not fully addressed
Yet, the problem is growing.
The breakthrough
A. Djellouli et al. Nature (2024)
The principle
Patented core technology
Our solution
The implant
First-of-its-kind soft, stent-like implant
Delivered via a 20-minute procedure similar to a stent
Descending aorta for systemic efficacy
End-organ protection e.g. to target renal HT
Patented implant technology
How it works
The implant passively senses blood pressure
In the systolic phase, the soft shells only activate if the pressure exceeds the healthy level
In the diastolic phase, the soft shells reset when the pressure decreases in the healthy range